List of Clinical Trials (found)

Disclaimer:

There are no currently approved treatments for Long Covid.Β However, some research is underway, and many of the systemic effects and symptoms of Long Covid can be improved by medical, supplemental, and/or mental health interventions.Β Any treatment, including supplements, should be discussed with a health professional before attempting.

Go Back To List of Clinical Trials (MOC)

List

  1. RSLV-132 (Resolve Therapeutics)

    • Mechanism: Enzymatically active ribonuclease designed to reduce inflammation.
    • Description: Phase 2 trial fully enrolled, with last participant completing in January 2023.
    • Results Expected: March 2023.
    • Clinical Trial Link: NCT04944121

  2. Ampligen (AIM ImmunoTech)

    • Mechanism: Low molecular weight filtrate that modulates the inflammatory cytokine levels.
    • Description: Small open-label study showed improvement in COVID-19 recovery.
    • Results Expected: December 2023.
    • Clinical Trial Links: NCT05592418, Ampligen Additional Info

  3. Low Dose Lithium

    • Mechanism: Not specified.
    • Results Expected: June 2023.
    • Clinical Trial Link: NCT05618587

  4. Paxlovid (Stanford study)

    • Mechanism: Antiviral to clear viral reservoirs.
    • Results Expected: November 2023.
    • Clinical Trial Link: NCT05576662

  5. Pimozide

    • Mechanism: Not specified.
    • Results Expected: December 2023.
    • Clinical Trial Link: NCT05507372

  6. Vortioxetine

    • Mechanism: Not specified.
    • Results Expected: February/March 2023.
    • Clinical Trial Link: NCT05047952

  7. Temelimab (GeNeuro)

    • Mechanism: Targets expression of HERV-W-ENV protein related to inflammation and neurologic symptoms.
    • Description: Phase 2 study on neuropsychiatric symptoms in post-COVID 19.
    • Results Expected: April 2023.
    • Clinical Trial Link: NCT05497089

  8. Efgartigimod

    • Mechanism: Not specified.
    • Results Expected: December 2023.
    • Clinical Trial Link: NCT05633407

  9. IVIG (intravenous immunoglobulin)

    • Mechanism: Modulates immune response, neutralizes pathogenic autoantibodies.
    • Description: NIH study on long-term high-dose immunoglobulin.
    • Results Expected: Possibly by end of 2023.
    • Clinical Trial Links: NCT05350774, IVIG Study

  10. BC007 (Berlin Cures)

    • Mechanism: Neutralizes autoantibodies against G protein-coupled receptors.
    • Description: Phase 2, study to start in 2023 with 100+ participants across Europe.
    • Location: Germany, Switzerland, Austria, Finland, Spain.

  11. Ibudilast / Pentoxifylline (University Health Network)

    • Mechanism: Anti-inflammatory and neuroprotective effects.
    • Description: Phase 2-3, RECLAIM study with 1000 participants, testing Ibudilast and Pentoxifylline.
    • Results Expected: July 2025.
    • Clinical Trial Link: NCT05513560

  12. Zofin (Organicell Regenerative Medicine)

    • Mechanism: Derived from perinatal sources to maintain microRNAs.
    • Description: Phase I/II trial.
    • Clinical Trial Link: NCT05228899

  13. Stem cells

  14. Ezrine peptides

  15. Plasmapheresis

    • Mechanism: Removes auto-antibodies from blood.
    • Clinical Trial Link: NCT05543590

  16. Amphion (Ampio Pharmaceuticals)

    • Mechanism: Low molecular weight filtrate of human serum albumin with the ability to modulate in vitro inflammatory cytokine levels.
    • Phase: Small open-label study showed improvement in COVID-19 recovery, with significant reduction in inflammation.

  17. Leronlimab (CytoDyn)

    • Mechanism: CCR5-binding antibody.
    • Description: Phase 2 trial observing increased blood cell surface CCR5 in treated symptomatic responders.
    • Location: Not specified in the provided text.

  18. Autologous mesenchymal cell therapy (ATCell; American CryoStem Corp)

    • Mechanism: Not specified in the provided text.
    • Description: Phase 1, single-center, double-blinded, placebo-controlled study.

  19. Anakinra

    • Mechanism: Anti-IL-1 mAb.

  20. Methylprednisolone

    • Mechanism: Synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties.

  21. Nivolumab or Ipilumab

    • Mechanism: Immune-checkpoint blockade to enhance T cell immunity.

  22. Rinetolimod

    • Mechanism: Poly(I:C)-like TLR stimulation.

  23. Siltuximab

    • Mechanism: Anti-IL-6 mAb.

  24. Sirolimus

    • Mechanism: T cell inhibition.

  25. Zilucoplan

    • Mechanism: Inhibits C5 cleavage.

  26. ARCT-021 COVID-19 vaccine

    • Mechanism: Boosts immunity to augment virus clearance.

  27. COVID-19 mRNA booster vaccine

    • Mechanism: Boosts immunity to augment virus clearance.

  28. Infliximab

    • Mechanism: mAb to clear viral reservoirs.

  29. Faecal microbiota transplantation

    • Mechanism: Reverses dysbiosis.

  30. Probiotics

    • Mechanism: Reverses dysbiosis.

  31. Cannabidiol

    • Mechanism: Relief from symptoms, including pain and movement problems.

  32. CoEnzyme Q10

    • Mechanism: Improves mitochondrial function.

  33. Ivabradine

    • Mechanism: Treatment of heart failure.

  34. Niagen, vitamin B3

    • Mechanism: Effects on mood and cognitive function.

  35. PB1046

    • Mechanism: VIP analogue.

  36. S1226

    • Mechanism: Bronchodilator.

  37. Somatropin

    • Mechanism: Human growth hormone.

  38. Vagus nerve stimulation

    • Mechanism: Anti-inflammatory and anti-pain.

  39. TNX-102 SL (Tonix Pharmaceuticals, Inc)

    • Mecanismo y descripciΓ³n: No especificado en el texto proporcionado.

  40. Deupirfenidone (LYT-100-COV; PureTech Health)

    • Mecanismo y descripciΓ³n: No especificado en el texto proporcionado.

  41. Immunoadsorption

    • Mecanismo: EliminaciΓ³n de autoanticuerpos de la sangre.

  42. Levonlimab

    • Mecanismo: Dirigido al receptor CCR5 en cΓ©lulas T.

  43. Pentoxifylline

    • Mecanismo: Inhibidor de la fosfodiesterasa antiinflamatorio.

  44. Sargramostim

    • Mecanismo: Promueve la estimulaciΓ³n inmune por GM-CSF.

Tables

# Treatment Mechanism Description Results Expected Clinical Trial Link
1 Anakinra Anti-IL-1 mAb
2 Amphion (Ampio Pharmaceuticals) Low molecular weight filtrate of human serum albumin with the ability to modulate in vitro inflammatory cytokine levels Small open-label study showed improvement in COVID-19 recovery, with significant reduction in inflammation
3 ARCT-021 COVID-19 vaccine Boosts immunity to augment virus clearance
4 Autologous mesenchymal cell therapy (ATCell; American CryoStem Corp) Not specified in the provided text Phase 1, single-center, double-blinded, placebo-controlled study
5 Ampligen (AIM ImmunoTech) Low molecular weight filtrate that modulates the inflammatory cytokine levels Small open-label study showed improvement in COVID-19 recovery December 2023 NCT05592418, Ampligen Additional Info
6 BC007 (Berlin Cures) Neutralizes autoantibodies against G protein-coupled receptors Phase 2, study to start in 2023 with 100+ participants across Europe
7 Cannabidiol Relief from symptoms, including pain and movement problems
8 CoEnzyme Q10 Improves mitochondrial function
9 COVID-19 mRNA booster vaccine Boosts immunity to augment virus clearance
10 Deupirfenidone (LYT-100-COV; PureTech Health) Not specified in the text Phase 2 trial did not show improvement
11 Efgartigimod Not specified December 2023 NCT05633407
12 Ezrine peptides Not specified Ammes Ezrine Peptides
13 Faecal microbiota transplantation Reverses dysbiosis
14 Ibudilast / Pentoxifylline (University Health Network) Anti-inflammatory and neuroprotective effects Phase 2-3, RECLAIM study with 1000 participants, testing Ibudilast and Pentoxifylline July 2025 NCT05513560
15 Immunoadsorption Elimination of autoantibodies from blood
16 Infliximab mAb to clear viral reservoirs
17 IVIG (intravenous immunoglobulin) Modulates immune response, neutralizes pathogenic autoantibodies NIH study on long-term high-dose immunoglobulin Possibly by end of 2023 NCT05350774, IVIG Study
18 Ivabradine Treatment of heart failure
19 Leronlimab (CytoDyn) CCR5-binding antibody Phase 2 trial observing increased blood cell surface CCR5 in treated symptomatic responders
20 Levonlimab Directed at CCR5 receptor on T cells
21 Low Dose Lithium Not specified June 2023 NCT05618587
22 Methylprednisolone Synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties
23 Niagen, vitamin B3 Effects on mood and cognitive function
24 Nivolumab or Ipilumab Immune-checkpoint blockade to enhance T cell immunity
25 Paxlovid (Stanford study) Antiviral to clear viral reservoirs November 2023 NCT05576662
26 PB1046 VIP analogue
27 Pentoxifylline Anti-inflammatory phosphodiesterase inhibitor
28 Pimozide Not specified December 2023 NCT05507372
29 Plasmapheresis Removes auto-antibodies from blood NCT05543590
30 Probiotics Reverses dysbiosis
31 Rinetolimod Poly(I:C)-like TLR stimulation
32 RSLV-132 (Resolve Therapeutics) Enzymatically active ribonuclease designed to reduce inflammation Phase 2 trial fully enrolled, with last participant completing in January 2023 March 2023 NCT04944121
33 S1226 Bronchodilator
34 Sargramostim Promotes immune stimulation by GM-CSF
35 Sirolimus T cell inhibition
36 Siltuximab Anti-IL-6 mAb
37 Somatropin Human growth hormone
38 Stem cells Not specified NCT05669261, American CryoStem Science
39 Temelimab (GeNeuro) Targets expression of HERV-W-ENV protein related to inflammation and neurologic symptoms Phase 2 study on neuropsychiatric symptoms in post-COVID 19 April 2023 NCT05497089
40 TNX-102 SL (Tonix Pharmaceuticals, Inc) Not specified in the text
41 Vagus nerve stimulation Anti-inflammatory and anti-pain
42 Vortioxetine Not specified February/March 2023 NCT05047952
43 Zilucoplan Inhibits C5 cleavage
44 Zofin (Organicell Regenerative Medicine) Derived from perinatal sources to maintain microRNAs Phase I/II trial NCT05228899

Go Back To List of Clinical Trials (MOC)